Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295256629> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4295256629 endingPage "AB107" @default.
- W4295256629 startingPage "AB107" @default.
- W4295256629 abstract "As the use of immune checkpoint inhibitors (ICI) in cancer treatment regimens continues to rise, so has the incidence of immune-related cutaneous adverse events (irCAEs). Among irCAEs, ICI-induced scleroderma and systemic sclerosis (SSc) are rare and poorly understood. We present a case of progressive and debilitating scleroderma-like changes in a 78-year-old female being treated with durvalumab (anti-PD-L1) for squamous cell carcinoma of the lung. After 12 treatments, the patient started to develop painful skin thickening, fibrosis, and erosions of the hands, ankles, feet, and ankles that subsequently worsened after treatment completion. A full-thickness biopsy confirmed the diagnosis of fibrosing dermatitis. Laboratory values were significant for a positive homogenous ANA (1:320) and an elevated C-reactive protein. The patient’s scleroderma proceeded to involve most of her trunks, arms, and legs despite treatment with hydroxychloroquine, systemic corticosteroids, mycophenolate mofetil, intravenous immunoglobulin, and apremilast. There have been less than 10 cases of limited cutaneous and diffuse cutaneous sclerosis reported in the literature following treatment with anti-PD-1 agents. To our knowledge, this is the first case of scleroderma following anti-PD-L1 therapy. As in this patient, ICI-induced scleroderma can be recalcitrant and can significantly impact quality of life. Patients on ICIs should be carefully examined for scleroderma-like changes as early recognition and treatment initiation could reduce disease severity and lead to improved tolerance to ICIs." @default.
- W4295256629 created "2022-09-12" @default.
- W4295256629 creator A5042473317 @default.
- W4295256629 creator A5052162166 @default.
- W4295256629 creator A5082083265 @default.
- W4295256629 date "2022-09-01" @default.
- W4295256629 modified "2023-09-27" @default.
- W4295256629 title "31789 Scleroderma associated with immune checkpoint inhibitor durvalumab" @default.
- W4295256629 doi "https://doi.org/10.1016/j.jaad.2022.06.461" @default.
- W4295256629 hasPublicationYear "2022" @default.
- W4295256629 type Work @default.
- W4295256629 citedByCount "1" @default.
- W4295256629 countsByYear W42952566292022 @default.
- W4295256629 crossrefType "journal-article" @default.
- W4295256629 hasAuthorship W4295256629A5042473317 @default.
- W4295256629 hasAuthorship W4295256629A5052162166 @default.
- W4295256629 hasAuthorship W4295256629A5082083265 @default.
- W4295256629 hasConcept C121608353 @default.
- W4295256629 hasConcept C126322002 @default.
- W4295256629 hasConcept C141071460 @default.
- W4295256629 hasConcept C16005928 @default.
- W4295256629 hasConcept C180032290 @default.
- W4295256629 hasConcept C197934379 @default.
- W4295256629 hasConcept C203014093 @default.
- W4295256629 hasConcept C2776670291 @default.
- W4295256629 hasConcept C2777217379 @default.
- W4295256629 hasConcept C2777701055 @default.
- W4295256629 hasConcept C2777742743 @default.
- W4295256629 hasConcept C2778456530 @default.
- W4295256629 hasConcept C2779075594 @default.
- W4295256629 hasConcept C2779123688 @default.
- W4295256629 hasConcept C2779134260 @default.
- W4295256629 hasConcept C2779967694 @default.
- W4295256629 hasConcept C2780030458 @default.
- W4295256629 hasConcept C3008058167 @default.
- W4295256629 hasConcept C524204448 @default.
- W4295256629 hasConcept C71924100 @default.
- W4295256629 hasConceptScore W4295256629C121608353 @default.
- W4295256629 hasConceptScore W4295256629C126322002 @default.
- W4295256629 hasConceptScore W4295256629C141071460 @default.
- W4295256629 hasConceptScore W4295256629C16005928 @default.
- W4295256629 hasConceptScore W4295256629C180032290 @default.
- W4295256629 hasConceptScore W4295256629C197934379 @default.
- W4295256629 hasConceptScore W4295256629C203014093 @default.
- W4295256629 hasConceptScore W4295256629C2776670291 @default.
- W4295256629 hasConceptScore W4295256629C2777217379 @default.
- W4295256629 hasConceptScore W4295256629C2777701055 @default.
- W4295256629 hasConceptScore W4295256629C2777742743 @default.
- W4295256629 hasConceptScore W4295256629C2778456530 @default.
- W4295256629 hasConceptScore W4295256629C2779075594 @default.
- W4295256629 hasConceptScore W4295256629C2779123688 @default.
- W4295256629 hasConceptScore W4295256629C2779134260 @default.
- W4295256629 hasConceptScore W4295256629C2779967694 @default.
- W4295256629 hasConceptScore W4295256629C2780030458 @default.
- W4295256629 hasConceptScore W4295256629C3008058167 @default.
- W4295256629 hasConceptScore W4295256629C524204448 @default.
- W4295256629 hasConceptScore W4295256629C71924100 @default.
- W4295256629 hasIssue "3" @default.
- W4295256629 hasLocation W42952566291 @default.
- W4295256629 hasOpenAccess W4295256629 @default.
- W4295256629 hasPrimaryLocation W42952566291 @default.
- W4295256629 hasRelatedWork W1884142790 @default.
- W4295256629 hasRelatedWork W2016343563 @default.
- W4295256629 hasRelatedWork W2048674643 @default.
- W4295256629 hasRelatedWork W2140192726 @default.
- W4295256629 hasRelatedWork W2255581583 @default.
- W4295256629 hasRelatedWork W3016008604 @default.
- W4295256629 hasRelatedWork W3024242606 @default.
- W4295256629 hasRelatedWork W3034692863 @default.
- W4295256629 hasRelatedWork W4225123739 @default.
- W4295256629 hasRelatedWork W1885445542 @default.
- W4295256629 hasVolume "87" @default.
- W4295256629 isParatext "false" @default.
- W4295256629 isRetracted "false" @default.
- W4295256629 workType "article" @default.